CMS Opens National Coverage Determination for Microvolt T-Wave Alternans Test.

BEDFORD, Mass. -- Cambridge Heart (OTCBB:CAMH) today announced that the Centers for Medicare and Medicaid Services (CMS) have opened a National Coverage Determination (NCD) for Microvolt T-Wave Alternans (MTWA).

The Medicare NCD process is intended to provide uniform coverage of innovative medical technologies across the entire country. Most Medicare coverage decisions are made on a local level by the numerous local carriers. The NCD process is a 6-9 month process whereby CMS seeks public comment and evaluates the evidence to determine if a medical item, service, procedure or technology is reasonable and necessary for the diagnosis or treatment of Medicare patients.

"We are very pleased that CMS decided to open the NCD based on data demonstrating MTWA's clinical value in the specific patient populations newly eligible for ICD implantation." stated David A. Chazanovitz, President and CEO of Cambridge Heart, Inc. "Following Medicare's NCD for implantable cardioverter defibrillators (ICDs) for MADIT II and SCD-HeFT patients, it became clear to us that an NCD would be necessary so that MTWA data could be more broadly available to physicians treating Medicare beneficiaries. With its clinical value as a negative predictor of the risk of sudden cardiac death, MTWA can help physicians direct ICD therapy and assure the most appropriate care for our senior citizens."

Mr. Chazanovitz added, "Currently, MTWA is covered by most local Medicare carriers under CPT code 93025. The basis of our request is to expand current CMS coverage policy to include those individuals who are now eligible for ICDs as primary prevention for sudden cardiac death. The MTWA NCD is currently the subject of a 30- day public comment period."

The tracking page for the NCD can be found at: http://www.cms.hhs.gov/mcd/viewtrackingsheet.asp?id=165

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or at risk of life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com

Statements contained in this press release that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include customer delays in making final buying decisions, decreased demand for our products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Annual Report on Form 10-K under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.